Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2019-05-30 Director's Dealing
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
Director's Dealing 2019
Director's Dealing
2019-05-30 English
Director's Dealing 2019
Director's Dealing
2019-05-24 English
Director's Dealing 2019
Director's Dealing
2019-05-23 English
FORM 10-Q
Interim / Quarterly Report Q3 2019
2019-05-16 English
NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the quarterly report on Form 10-Q for the period ended March 31, 2019, could not be filed on time due to the inability to finalize unaudited financial statements without unreasonable effort and expense. The form indicates that the 10-Q report is being filed simultaneously with this notification. The document does not contain the actual financial statements or substantive financial data but is a regulatory notification about the delay in filing the 10-Q report. According to the rules, such a certification or notification document should be classified as a Regulatory Filing (RNS) rather than the actual Interim/Quarterly Report (IR).
2019-05-16 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 1, 2019, by Enochian Biosciences Inc. It announces the availability of an investor presentation titled 'Meet Enochian BioSciences' attached as Exhibit 99.1. The text explicitly states that the presentation is furnished with the report and is incorporated by reference. The document itself is short (3675 characters) and primarily serves to disclose the availability of the investor presentation rather than containing detailed financial data or analysis. According to the classification rules, such a document is best classified as an Investor Presentation (IP) because it is a detailed presentation for investors focusing on financials, strategy, and market position, and it is attached as an exhibit to the 8-K. The document is not a full financial report, earnings release, or regulatory filing beyond the 8-K form itself. Therefore, the appropriate classification is Investor Presentation (IP).
2019-05-01 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.